Two HDAC inhibitors, SAHA (vorinostat) and FK228 (romidepsin), have been approved by FDA for the treatment of CTCL [13], indicating that HDAC is an important target for tumor therapy. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.